Hypercholesterolemia and a candidate gene within the 12q24 locus by Gragnoli, Claudia
ORIGINAL INVESTIGATION Open Access
Hypercholesterolemia and a candidate gene
within the 12q24 locus
Claudia Gragnoli
1,2,3
Abstract
Background: The 12q24 locus entails at least one gene responsible for hypercholesterolemia. Within the
12q24 locus lies the gene of proteasome modulator 9 (PSMD9). PSMD9 is in linkage with type 2 diabetes (T2D),
T2D-nephropathy and macrovascular pathology in Italian families and PSMD9 rare mutations contribute to T2D.
Aims: In the present study, we aimed at determining whether the PSMD9 T2D risk single nucleotide
polymorphisms (SNPs) IVS3 + nt460 A > G, IVS3 + nt437 T > C and E197G A > G are linked to hypercholesterolemia
in 200 T2D Italian families.
Methods: We characterized 200 Italian families for presence and/or absence of hypercholesterolemia characterized
by LDL levels ≥ 100 mg/dl in drug-naïve patients and/or presence of a diagnosis of hypercholesterolemia in a
patient treated with statin medication. The phenotypes were described as unknown in all cases in which the
diagnosis was either unclear or the data were missing. We tested in the 200 Italians families for evidence of linkage
of the PSMD9 SNPs with hypercholesterolemia. The non-parametric linkage analysis was performed for the
qualitative phenotype by using the Merlin software; the Lod score and correspondent P-value were calculated. For
the significant linkage score, 1000 replicates were performed to calculate the empirical P-value.
Results: The PSMD9 gene SNPs studied show linkage to hypercholesterolemia. The results are not due to random
chance.
Conclusions: PSMD9 should be tested in all populations reporting linkage to hypercholesterolemia within the
chromosome 12q24 locus. The impact of this gene on hypercholesterolemia and contribution to cardio- and
cerebrovascular events may be high.
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Introduction
The chromosome 12q24 locus is linked to dyslipidemia
and hypercholesterolemia and must entail at least one
gene responsible for these phenotypes [1,2]. Dyslipidemia
is an important cardiovascular risk factor for T2D. Dysli-
pidemia is a major modifiable risk factor of atherosclero-
sis, which introduces the possibility of both treatment
and prevention of the cardiovascular complications of
T2D [3].
Within the 12q24 locus is located the gene of protea-
some modulator 9 (PSMD9). PSMD 9 is highly expressed
in pancreatic islets and it is a coactivator of insulin gene
transcription, and PSMD9 gene dosage abnormalities
cause beta-cell dysfunction and contribute to type 2 dia-
betes (T2D) [4]. PSMD9 is a ubiquitously expressed pro-
tein. We reported that PSMD9 rarely causes T2D by
unique mutations [5] and that the P S M D 9I V S 3+n t 4 6 0
A > G, IVS3 + nt437 C > T and E197G A > G single
nucleotide polymorphisms (SNPs) are linked to late-onset
T2D via the recessive model [6] and to MODY3 [7] via
the additive model. We recently published that the
P S M D 9I V S 3+n t 4 6 0A>G ,I V S 3+n t 4 3 7C>Tand
E197G A > G T2D risk SNPs are linked to T2D-nephropa-
thy [8] as well as to macrovascular pathology [9]. Insulin is
a lipid-synthetic hormone, thus alteration in a gene regu-
lating insulin gene transcription may alter lipid metabo-
lism as well and contribute to hypercholesterolemia.
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coactivator Bridge-1, homologous of PSMD9, results in
elevated triglyceride levels in Bridge-1/PSMD9 with severe
diabetes compared to non-transgenic control mice [10].
We aimed at identifying in the present study whether
the coactivator of insulin transcription PSMD9 may con-
tribute to linkage to hypercholesterolemia in 200 Italian
T2D families. Thus, we tested the PSMD9 T2D risk
SNPs for linkage to hypercholesterolemia.
Methods
Ethics Statement
the subjects were all recruited following the Helsinki
declaration guidelines. Subjects gave written informed
consent and the Penn State College of Medicine Ethical
Committee approved the study.
Families
We recruited 200 Italian T2D affected siblings and
families. We excluded families with identical twins and
we confirmed that our families were at least for three
generations Italians and had no known ancestor of not-
Italian origin. The Italian population lives in a peninsula
and it is very suitable for genetic studies as there are no
concerns for genetic admixture.
Clinical Phenotyping
We characterized the Italian family’s subjects, including
those unaffected by T2D, for LDL cholesterol ≥100 mg/dl
in drug-naïve patients and/or presence of hypercholestero-
lemia in patients treated with statin medication.
Phenotypes are described as unknown if diagnosis is
unclear or data are missing. In our 200 Italian families,
hypercholesterolemia is present in 87.30% of the families.
Sequencing
We amplified by PCR the IVS3 PSMD9 region contain-
ing the +nt460 A > G and +nt437 C > T SNPs and the
exon 5 coding region containing the E197G A > G SNP
with specific primers [5] in the affected and unaffected
family members. We directly sequenced the PCR pro-
ducts, status post-purification via EXOSAP-IT on an
automated ABI 3730 Sequencer.
Statistical Analysis
We tested in the 200 Italians families for linkage of the
PSMD9 above-mentioned SNPs with hypercholesterole-
mia. Non-parametric linkage analysis for the qualitative
phenotype was performed for the three SNPs via the
latest version of Merlin software [11]. Merlin analyzed
all the informative families (n = 84) within this dataset.
The number of individuals in the 200 families is 928;
the number of individuals in the 84 families is 390
(table 1).
Allele frequencies were calculated from the data. The
result is reported in LOD score as calculated by Merlin.
To rule out the presence of a false positive in our
result, we calculated how many times P-values equal or
inferior to the real one were expected by chance in
1,000 replicates of simulations by using the gene drop-
ping method: this analysis replaces real data with simu-
lated data, while maintaining the pedigree structure,
allele frequencies and recombination fraction. These
datasets are generated under the null hypothesis of no
linkage.
Results
The results of the non-parametric linkage analysis per-
formed are reported in table 2 with the LOD score, the
corresponding P-value and the empirical P-value. The
tested PSMD9 SNPs are significantly linked to hyperch-
olesterolemia in the T2D-families. The three variants
tested contribute almost equally to the results, with a
non significant prevalence of t h ei n t r o n i cv a r i a n t so v e r
the coding variant.
Discussion
Our study shows that the PSMD9 SNPs studied are in
linkage with hypercholesterolemia in the Italian T2D
families, thus making PSMD9 ap o s s i b l er i s kg e n ef o r
hypercholesterolemia. However, these findings should be
replicated in families with hypercholesterolemia of other
ethnicities and in particular in all ethnical groups in
which the chromosome 12q24 locus was reported as
linked to elevated cholesterol [1,2] to confirm the gen-
eral relevance of the gene in other populations as well.
Table 1 Population Demographics
Population T2D
Families/
Subjects
Sex (F/M) Families Informative
for Hypercholes-
terolemia/Subjects
Sex (F/M)
100%
Italians
200/928 467/461 84/390 199/191
F = female, M = male.
Table 2 Non-parametric Linkage Analysis of
Hypercholesterolemia of the Italian Families by Merlin
software
Phenotype Prevalence Families Z
Score
Lod P Empirical
P
Hypercholes-
terolemia
87.30% 84 2.12 1.24 0.008 0.007
Prevalence = phenotype prevalence among the family subjects studied;
Families = families number analyzed; Z score = derived from the non-
parametric linkage analysis by Merlin; Lod = Lod score derived from the non-
parametric linkage analysis by Merlin; P = p-value; Empirical P = p-value
derived from 1000 replicates by using the gene dropping method;
Hypercholesterolemia defined by the presence of LDL ≥ 100 mg/dl in drug-
naïve patients or by the presence of a diagnosis of hypercholesterolemia
treated with a statin medication.
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impact given the relevan c eo ft h e1 2 q 2 4l o c u si n
hypercholesterolemia in several ethnical groups [1,2] as
well as the importance of hypercholesterolemia as a
major risk factor for macrovascular disease and cerebral
and cardiovascular events reducing quality of life and
lifetime span [3]. Given the PSMD9 linkage reported
with T2D-nephropathy [8] and with macrovascular
pathology [9] as well, it is possible that the PSMD9 has
pleiotropic effects contributing to the phenotypes asso-
ciated with macrovascular pathology as well as with
T2D. PSMD9 is present at high concentrations in eukar-
yotic cells and is part of the 26S proteasome complex,
which contributes to the degradation of intracellular
proteins in antigenic peptides in the immune response
to antigen presentation by MHC class I cells (http://
www.genecards.org/cgi-bin/carddisp.pl?gene=PSMD9).
Thus, one potential role of PSMD9 in the phenotypes
associated with T2D and atherosclerosis could be related
to a direct role in the pathogenesis of inflammation as an
autoimmune process [12]. In addition, PSMD9 is mediat-
ing the magnitude and duration of the transcription of
the ligand-dependent retinoid-target genes (http://www.
millipore.com/pathways/pathviewer.do?pathwayId=76).
Thus, PSMD9 may, if impaired in its function due to
gene variants affecting the protein sequence and/or pro-
tein dosage, alter dosage and effects of several down-
stream genes. In transgenic mice with pancreatic
overexpression of the homologous of PSMD9, it has been
shown that the increased dose of the PSMD9 protein is
causing insulin deficiency and diabetes as well as hyper-
triglyceridemia [10]. In addition, an inhibition of the gene
transcription in vitro also reduces insulin secretion [13].
Thus, the hypothesis is that given the complex network
of transcription and co-activator factors that PSMD9 is
associated to, both PSMD9 reduced or increased protein
dose in the cell may have pathogenetic effects, by poten-
tially contributing to phenotypes that may be either dif-
ferent or having an underlying contributing factor.
Conclusions
We conclude that the PSMD9 SNPs IVS3 + nt460 A >
G, IVS3 + nt437 C > T and E197G A > G are linked to
the hypercholesterolemia phenotype in the Italian T2D-
families tested. This finding is of relevance as hypercho-
lesterolemia is a major contributor of cardiovascular dis-
ease in T2D, and thus the identification of genes
implicated in the pathogenesis of hypercholesterolemia
may lead to future primary and secondary prevention
therapies implementations.
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